LABELS · 990c5dd1-5670-4e2f-af5d-6e87b73b12b5

BAVENCIO

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2026-08-25
Captured: 2026-09-09T23:37:54.830918+00:00
Current indication reconciliation: Not reconciled

Indications and usage: exact source text

1 INDICATIONS AND USAGE BAVENCIO is a programmed death ligand-1 (PD-L1) blocking antibody indicated for: Merkel Cell Carcinoma (MCC) Adults and pediatric patients 12 years and older with metastatic MCC. ( 1.1 , 14.1 ) Urothelial Carcinoma (UC) Maintenance treatment of patients with locally advanced or metastatic UC that has not progressed with first-line platinum-containing chemotherapy. ( 1.2 , 14.2 ) Patients with locally advanced or metastatic UC who: Have disease progression during or following platinum-containing chemotherapy. ( 1.2 , 14.2 ) Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.2 , 14.2 ) Renal Cell Carcinoma (RCC) First-line treatment, in combination with axitinib, of patients with advanced RCC. ( 1.3 , 14.3 ) 1.1 Metastatic Merkel Cell Carcinoma BAVENCIO (avelumab) is indicated for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC) [see Clinical Studies (14.1) ] . 1.2 Locally Advanced or Metastatic Urothelial Carcinoma First-Line Maintenance Treatment of Urothelial Carcinoma BAVENCIO is indicated for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy [see Clinical Studies (14.2) ] . Previously-treated Urothelial Carcinoma BAVENCIO is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) who: Have disease progression during or following platinum-containing chemotherapy Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy [see Clinical Studies (14.2) ]. 1.3 Advanced Renal Cell Carcinoma BAVENCIO in combination with axitinib is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC) [see Clinical Studies (14.3) ] .

Full extracted label fields

application numbers

BLA761049

boxed warning exact

brand names

BAVENCIO

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5cd725a1-2fa4-408a-a651-57a7b84b2118

generic names

AVELUMAB

990c5dd1-5670-4e2f-af5d-6e87b73b12b5

indications and usage exact

1 INDICATIONS AND USAGE BAVENCIO is a programmed death ligand-1 (PD-L1) blocking antibody indicated for: Merkel Cell Carcinoma (MCC) Adults and pediatric patients 12 years and older with metastatic MCC. ( 1.1 , 14.1 ) Urothelial Carcinoma (UC) Maintenance treatment of patients with locally advanced or metastatic UC that has not progressed with first-line platinum-containing chemotherapy. ( 1.2 , 14.2 ) Patients with locally advanced or metastatic UC who: Have disease progression during or following platinum-containing chemotherapy. ( 1.2 , 14.2 ) Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.2 , 14.2 ) Renal Cell Carcinoma (RCC) First-line treatment, in combination with axitinib, of patients with advanced RCC. ( 1.3 , 14.3 ) 1.1 Metastatic Merkel Cell Carcinoma BAVENCIO (avelumab) is indicated for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC) [see Clinical Studies (14.1) ] . 1.2 Locally Advanced or Metastatic Urothelial Carcinoma First-Line Maintenance Treatment of Urothelial Carcinoma BAVENCIO is indicated for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy [see Clinical Studies (14.2) ] . Previously-treated Urothelial Carcinoma BAVENCIO is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) who: Have disease progression during or following platinum-containing chemotherapy Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy [see Clinical Studies (14.2) ]. 1.3 Advanced Renal Cell Carcinoma BAVENCIO in combination with axitinib is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC) [see Clinical Studies (14.3) ] .

indications and usage tables exact

is original packager

true

manufacturer names

EMD Serono, Inc.

matched search terms

carcinoma

package ndcs

44087-3535-1

product ndcs

44087-3535

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

Warnings and Precautions ( 5.1 ) 07/2026

record type

complete_spl_indications_section_candidate

routes

INTRAVENOUS

rxcuis

1875542
1875547

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00500.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

BLA761049

brand names

BAVENCIO

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 402
end exclusive: true
exact text: 1 INDICATIONS AND USAGE BAVENCIO is a programmed death ligand-1 (PD-L1) blocking antibody indicated for: Merkel Cell Carcinoma (MCC) Adults and pediatric patients 12 years and older with metastatic MCC. ( 1.1 , 14.1 ) Urothelial Carcinoma (UC) Maintenance treatment of patients with locally advanced or metastatic UC that has not progressed with first-line platinum-containing chemotherapy. ( 1.2 , 14.
label id: 990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start: 0

current approval status

not_reconciled

duplicate text group

dup-2b529d699bd2530cb923

extraction review status

automated_candidate_pending_source_review

generic names

AVELUMAB

ind-span-e9ceee13aa5379d7798c

label id

990c5dd1-5670-4e2f-af5d-6e87b73b12b5

positive predicate support span

end: 99
end exclusive: true
exact text: is a programmed death ligand-1 (PD-L1) blocking antibody indicated
label id: 990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start: 33

qualifier mentions

context exact
locking antibody indicated for: Merkel Cell Carcinoma (MCC) Adults and pediatric patients 12 years and older with metastatic M
kind
age
polarity
not_inferred
span
end
139
end exclusive
true
exact text
Adults
label id
990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start
133
context exact
ibody indicated for: Merkel Cell Carcinoma (MCC) Adults and pediatric patients 12 years and older with metastatic MCC.
kind
age
polarity
not_inferred
span
end
162
end exclusive
true
exact text
pediatric patients
label id
990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start
144
context exact
: Merkel Cell Carcinoma (MCC) Adults and pediatric patients 12 years and older with metastatic MCC.
kind
age
polarity
not_inferred
span
end
181
end exclusive
true
exact text
12 years and older
label id
990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start
163
context exact
ICATIONS AND USAGE BAVENCIO is a programmed death ligand-1 (PD-L1) blocking antibody indicated for: Merkel Cell Carcinoma (MCC) Adults and pediatric patients 12 year
kind
biomarker
polarity
not_inferred
span
end
110
end exclusive
true
exact text
PD-L1) blocking antibody indicated for: Merke
label id
990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start
65
context exact
(MCC) Adults and pediatric patients 12 years and older with metastatic MCC.
kind
biomarker
polarity
not_inferred
span
end
201
end exclusive
true
exact text
metastatic MCC
label id
990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start
187
context exact
(MCC) Adults and pediatric patients 12 years and older with metastatic MCC.
kind
stage_or_setting
polarity
not_inferred
span
end
201
end exclusive
true
exact text
metastatic MCC
label id
990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start
187

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 202
end exclusive: true
exact text: 1 INDICATIONS AND USAGE BAVENCIO is a programmed death ligand-1 (PD-L1) blocking antibody indicated for: Merkel Cell Carcinoma (MCC) Adults and pediatric patients 12 years and older with metastatic MCC.
label id: 990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%22990c5dd1-5670-4e2f-af5d-6e87b73b12b5%22

spl effective date

2026-08-25

spl set id

5cd725a1-2fa4-408a-a651-57a7b84b2118

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 2 · positive indication candidate

application numbers

BLA761049

brand names

BAVENCIO

classification reasons

inherited_predicate_from_same_label_section_requires_review
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 590
end exclusive: true
exact text: NDICATIONS AND USAGE BAVENCIO is a programmed death ligand-1 (PD-L1) blocking antibody indicated for: Merkel Cell Carcinoma (MCC) Adults and pediatric patients 12 years and older with metastatic MCC. ( 1.1 , 14.1 ) Urothelial Carcinoma (UC) Maintenance treatment of patients with locally advanced or metastatic UC that has not progressed with first-line platinum-containing chemotherapy. ( 1.2 , 14.2 ) Patients with locally advanced or metastatic UC who: Have disease progression during or following platinum-containing chemotherapy. ( 1.2 , 14.2 ) Have disease progression within 12 mo
label id: 990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start: 3

current approval status

not_reconciled

duplicate text group

dup-a6b8e83260dec0b0e8cb

extraction review status

automated_candidate_pending_source_review

generic names

AVELUMAB

ind-span-991c1f6c8b91142ccc2d

label id

990c5dd1-5670-4e2f-af5d-6e87b73b12b5

positive predicate support span

end: 99
end exclusive: true
exact text: is a programmed death ligand-1 (PD-L1) blocking antibody indicated
label id: 990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start: 33

qualifier mentions

context exact
Maintenance treatment of patients with locally advanced or metastatic UC that has not progressed with first-line platinum-containing chemotherapy.
kind
biomarker
polarity
not_inferred
span
end
346
end exclusive
true
exact text
metastatic UC that has not progressed with
label id
990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start
303
context exact
elial Carcinoma (UC) Maintenance treatment of patients with locally advanced or metastatic UC that has not progressed with first-line platinum-containing chemotherapy.
kind
stage_or_setting
polarity
not_inferred
span
end
334
end exclusive
true
exact text
locally advanced or metastatic UC that has not prog
label id
990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start
283
context exact
ally advanced or metastatic UC that has not progressed with first-line platinum-containing chemotherapy.
kind
prior_therapy_or_line
polarity
not_inferred
span
end
389
end exclusive
true
exact text
first-line platinum-containing chemotherapy
label id
990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start
346

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 390
end exclusive: true
exact text: ( 1.1 , 14.1 ) Urothelial Carcinoma (UC) Maintenance treatment of patients with locally advanced or metastatic UC that has not progressed with first-line platinum-containing chemotherapy.
label id: 990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start: 203

source url

https://api.fda.gov/drug/label.json?search=id%3A%22990c5dd1-5670-4e2f-af5d-6e87b73b12b5%22

spl effective date

2026-08-25

spl set id

5cd725a1-2fa4-408a-a651-57a7b84b2118

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 3 · positive indication candidate

application numbers

BLA761049

brand names

BAVENCIO

classification reasons

inherited_predicate_from_same_label_section_requires_review
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 737
end exclusive: true
exact text: static MCC. ( 1.1 , 14.1 ) Urothelial Carcinoma (UC) Maintenance treatment of patients with locally advanced or metastatic UC that has not progressed with first-line platinum-containing chemotherapy. ( 1.2 , 14.2 ) Patients with locally advanced or metastatic UC who: Have disease progression during or following platinum-containing chemotherapy. ( 1.2 , 14.2 ) Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.2 , 14.2 ) Renal Cell Carcinoma (RCC) First-line treatment, in
label id: 990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start: 191

current approval status

not_reconciled

duplicate text group

dup-3fa67ff881ee975cb1a9

extraction review status

automated_candidate_pending_source_review

generic names

AVELUMAB

ind-span-e277aaa3238e4fa3705b

label id

990c5dd1-5670-4e2f-af5d-6e87b73b12b5

positive predicate support span

end: 99
end exclusive: true
exact text: is a programmed death ligand-1 (PD-L1) blocking antibody indicated
label id: 990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start: 33

qualifier mentions

context exact
( 1.2 , 14.2 ) Patients with locally advanced or metastatic UC who: Have disease progression during or following platinum-containing chemotherapy.
kind
biomarker
polarity
not_inferred
span
end
483
end exclusive
true
exact text
metastatic UC who: Have disease progression
label id
990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start
440
context exact
( 1.2 , 14.2 ) Patients with locally advanced or metastatic UC who: Have disease progression during or following platinum-containing chemoth
kind
stage_or_setting
polarity
not_inferred
span
end
471
end exclusive
true
exact text
locally advanced or metastatic UC who: Have disease
label id
990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start
420

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 537
end exclusive: true
exact text: ( 1.2 , 14.2 ) Patients with locally advanced or metastatic UC who: Have disease progression during or following platinum-containing chemotherapy.
label id: 990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start: 391

source url

https://api.fda.gov/drug/label.json?search=id%3A%22990c5dd1-5670-4e2f-af5d-6e87b73b12b5%22

spl effective date

2026-08-25

spl set id

5cd725a1-2fa4-408a-a651-57a7b84b2118

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 4 · unclassified context

application numbers

BLA761049

brand names

BAVENCIO

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 870
end exclusive: true
exact text: ed with first-line platinum-containing chemotherapy. ( 1.2 , 14.2 ) Patients with locally advanced or metastatic UC who: Have disease progression during or following platinum-containing chemotherapy. ( 1.2 , 14.2 ) Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.2 , 14.2 ) Renal Cell Carcinoma (RCC) First-line treatment, in combination with axitinib, of patients with advanced RCC. ( 1.3 , 14.3 ) 1.1 Metastatic Merkel Cell Carcinoma BAVENCIO (avelumab) is
label id: 990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start: 338

current approval status

not_reconciled

duplicate text group

dup-f80917d89c47d2dbac34

extraction review status

automated_candidate_pending_source_review

generic names

AVELUMAB

ind-span-bad0322c277da3138eb7

label id

990c5dd1-5670-4e2f-af5d-6e87b73b12b5

positive predicate support span

Source null

qualifier mentions

context exact
( 1.2 , 14.2 ) Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
kind
stage_or_setting
polarity
not_inferred
span
end
644
end exclusive
true
exact text
neoadjuvant or adjuvant treatment with platinu
label id
990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start
598

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 670
end exclusive: true
exact text: ( 1.2 , 14.2 ) Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
label id: 990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start: 538

source url

https://api.fda.gov/drug/label.json?search=id%3A%22990c5dd1-5670-4e2f-af5d-6e87b73b12b5%22

spl effective date

2026-08-25

spl set id

5cd725a1-2fa4-408a-a651-57a7b84b2118

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 5 · positive indication candidate

application numbers

BLA761049

brand names

BAVENCIO

classification reasons

inherited_predicate_from_same_label_section_requires_review
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 995
end exclusive: true
exact text: progression during or following platinum-containing chemotherapy. ( 1.2 , 14.2 ) Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.2 , 14.2 ) Renal Cell Carcinoma (RCC) First-line treatment, in combination with axitinib, of patients with advanced RCC. ( 1.3 , 14.3 ) 1.1 Metastatic Merkel Cell Carcinoma BAVENCIO (avelumab) is indicated for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC)
label id: 990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start: 471

current approval status

not_reconciled

duplicate text group

dup-a9bd15110e74cfd21a05

extraction review status

automated_candidate_pending_source_review

generic names

AVELUMAB

ind-span-590342f09447b6bec1f6

label id

990c5dd1-5670-4e2f-af5d-6e87b73b12b5

positive predicate support span

end: 99
end exclusive: true
exact text: is a programmed death ligand-1 (PD-L1) blocking antibody indicated
label id: 990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start: 33

qualifier mentions

context exact
e treatment, in combination with axitinib, of patients with advanced RCC.
kind
stage_or_setting
polarity
not_inferred
span
end
794
end exclusive
true
exact text
advanced RCC
label id
990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start
782
context exact
( 1.2 , 14.2 ) Renal Cell Carcinoma (RCC) First-line treatment, in combination with axitinib, of patients with advanced RCC.
kind
prior_therapy_or_line
polarity
not_inferred
span
end
794
end exclusive
true
exact text
First-line treatment, in combination with axitinib, of patients with advanced RCC
label id
990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start
713
context exact
2 , 14.2 ) Renal Cell Carcinoma (RCC) First-line treatment, in combination with axitinib, of patients with advanced RCC.
kind
regimen
polarity
not_inferred
span
end
794
end exclusive
true
exact text
in combination with axitinib, of patients with advanced RCC
label id
990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start
735

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 795
end exclusive: true
exact text: ( 1.2 , 14.2 ) Renal Cell Carcinoma (RCC) First-line treatment, in combination with axitinib, of patients with advanced RCC.
label id: 990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start: 671

source url

https://api.fda.gov/drug/label.json?search=id%3A%22990c5dd1-5670-4e2f-af5d-6e87b73b12b5%22

spl effective date

2026-08-25

spl set id

5cd725a1-2fa4-408a-a651-57a7b84b2118

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 6 · unclassified context

application numbers

BLA761049

brand names

BAVENCIO

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1010
end exclusive: true
exact text: f neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.2 , 14.2 ) Renal Cell Carcinoma (RCC) First-line treatment, in combination with axitinib, of patients with advanced RCC. ( 1.3 , 14.3 ) 1.1 Metastatic Merkel Cell Carcinoma BAVENCIO (avelumab) is indicated for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC) [see Clinical S
label id: 990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start: 596

current approval status

not_reconciled

duplicate text group

dup-743b74b598692985b0aa

extraction review status

automated_candidate_pending_source_review

generic names

AVELUMAB

ind-span-f5833cb8c344da686e80

label id

990c5dd1-5670-4e2f-af5d-6e87b73b12b5

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 810
end exclusive: true
exact text: ( 1.3 , 14.3 )
label id: 990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start: 796

source url

https://api.fda.gov/drug/label.json?search=id%3A%22990c5dd1-5670-4e2f-af5d-6e87b73b12b5%22

spl effective date

2026-08-25

spl set id

5cd725a1-2fa4-408a-a651-57a7b84b2118

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 7 · positive indication candidate

application numbers

BLA761049

brand names

BAVENCIO

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1227
end exclusive: true
exact text: r adjuvant treatment with platinum-containing chemotherapy. ( 1.2 , 14.2 ) Renal Cell Carcinoma (RCC) First-line treatment, in combination with axitinib, of patients with advanced RCC. ( 1.3 , 14.3 ) 1.1 Metastatic Merkel Cell Carcinoma BAVENCIO (avelumab) is indicated for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC) [see Clinical Studies (14.1) ] . 1.2 Locally Advanced or Metastatic Urothelial Carcinoma First-Line Maintenance Treatment of Urothelial Carcinoma BAVENCIO is indicated for the maintenance treatment of patients with locally advanced
label id: 990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start: 611

current approval status

not_reconciled

duplicate text group

dup-9c15a96cad3d3e791560

extraction review status

automated_candidate_pending_source_review

generic names

AVELUMAB

ind-span-6169636b68c08664c306

label id

990c5dd1-5670-4e2f-af5d-6e87b73b12b5

positive predicate support span

end: 880
end exclusive: true
exact text: is indicated
label id: 990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start: 868

qualifier mentions

context exact
inoma BAVENCIO (avelumab) is indicated for the treatment of adults and pediatric patients 12 years and older with metastatic M
kind
age
polarity
not_inferred
span
end
908
end exclusive
true
exact text
adults
label id
990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start
902
context exact
CIO (avelumab) is indicated for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (M
kind
age
polarity
not_inferred
span
end
931
end exclusive
true
exact text
pediatric patients
label id
990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start
913
context exact
ndicated for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC) [see Clinical S
kind
age
polarity
not_inferred
span
end
950
end exclusive
true
exact text
12 years and older
label id
990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start
932
context exact
1.1 Metastatic Merkel Cell Carcinoma BAVENCIO (avelumab) is indicated for the treatment of adults and pedia
kind
biomarker
polarity
not_inferred
span
end
858
end exclusive
true
exact text
Metastatic Merkel Cell Carcinoma BAVENCIO (
label id
990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start
815
context exact
nt of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC) [see Clinical Studies (14.1) ] .
kind
biomarker
polarity
not_inferred
span
end
999
end exclusive
true
exact text
metastatic Merkel cell carcinoma (MCC) [see
label id
990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start
956
context exact
1.1 Metastatic Merkel Cell Carcinoma BAVENCIO (avelumab) is indicated for the treatment of adults and pediatr
kind
stage_or_setting
polarity
not_inferred
span
end
860
end exclusive
true
exact text
Metastatic Merkel Cell Carcinoma BAVENCIO (av
label id
990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start
815
context exact
nt of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC) [see Clinical Studies (14.1) ] .
kind
stage_or_setting
polarity
not_inferred
span
end
1001
end exclusive
true
exact text
metastatic Merkel cell carcinoma (MCC) [see C
label id
990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start
956

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 1027
end exclusive: true
exact text: 1.1 Metastatic Merkel Cell Carcinoma BAVENCIO (avelumab) is indicated for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC) [see Clinical Studies (14.1) ] .
label id: 990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start: 811

source url

https://api.fda.gov/drug/label.json?search=id%3A%22990c5dd1-5670-4e2f-af5d-6e87b73b12b5%22

spl effective date

2026-08-25

spl set id

5cd725a1-2fa4-408a-a651-57a7b84b2118

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 8 · positive indication candidate

application numbers

BLA761049

brand names

BAVENCIO

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1572
end exclusive: true
exact text: rkel Cell Carcinoma BAVENCIO (avelumab) is indicated for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC) [see Clinical Studies (14.1) ] . 1.2 Locally Advanced or Metastatic Urothelial Carcinoma First-Line Maintenance Treatment of Urothelial Carcinoma BAVENCIO is indicated for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy [see Clinical Studies (14.2) ] . Previously-treated Urothelial Carcinoma BAVENCIO is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) who: Have disease progression during or follo
label id: 990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start: 828

current approval status

not_reconciled

duplicate text group

dup-51a44610ede6d9d01700

extraction review status

automated_candidate_pending_source_review

generic names

AVELUMAB

ind-span-e7563d697cf5c112d4f9

label id

990c5dd1-5670-4e2f-af5d-6e87b73b12b5

positive predicate support span

end: 1162
end exclusive: true
exact text: is indicated
label id: 990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start: 1150

qualifier mentions

context exact
1.2 Locally Advanced or Metastatic Urothelial Carcinoma First-Line Maintenance Treatment of Urothelial Carcinoma BAVENCIO is in
kind
biomarker
polarity
not_inferred
span
end
1095
end exclusive
true
exact text
Metastatic Urothelial Carcinoma First-Line
label id
990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start
1052
context exact
maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemot
kind
biomarker
polarity
not_inferred
span
end
1273
end exclusive
true
exact text
metastatic urothelial carcinoma (UC) that h
label id
990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start
1230
context exact
1.2 Locally Advanced or Metastatic Urothelial Carcinoma First-Line Maintenance Treatment of Urothelial Carcinoma BA
kind
stage_or_setting
polarity
not_inferred
span
end
1083
end exclusive
true
exact text
Locally Advanced or Metastatic Urothelial Carcinoma
label id
990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start
1032
context exact
is indicated for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-conta
kind
stage_or_setting
polarity
not_inferred
span
end
1261
end exclusive
true
exact text
locally advanced or metastatic urothelial carcinoma
label id
990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start
1210
context exact
1.2 Locally Advanced or Metastatic Urothelial Carcinoma First-Line Maintenance Treatment of Urothelial Carcinoma BAVENCIO is indicated for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinu
kind
prior_therapy_or_line
polarity
not_inferred
span
end
1254
end exclusive
true
exact text
First-Line Maintenance Treatment of Urothelial Carcinoma BAVENCIO is indicated for the maintenance treatment of patients with locally advanced or metastatic urothelial ca
label id
990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start
1084
context exact
atic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy [see Clinical Studies (14.2) ] .
kind
prior_therapy_or_line
polarity
not_inferred
span
end
1365
end exclusive
true
exact text
first-line platinum-containing chemotherapy [see Clinical Studies (14
label id
990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start
1296

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 1372
end exclusive: true
exact text: 1.2 Locally Advanced or Metastatic Urothelial Carcinoma First-Line Maintenance Treatment of Urothelial Carcinoma BAVENCIO is indicated for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy [see Clinical Studies (14.2) ] .
label id: 990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start: 1028

source url

https://api.fda.gov/drug/label.json?search=id%3A%22990c5dd1-5670-4e2f-af5d-6e87b73b12b5%22

spl effective date

2026-08-25

spl set id

5cd725a1-2fa4-408a-a651-57a7b84b2118

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 9 · positive indication candidate

application numbers

BLA761049

brand names

BAVENCIO

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1958
end exclusive: true
exact text: intenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy [see Clinical Studies (14.2) ] . Previously-treated Urothelial Carcinoma BAVENCIO is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) who: Have disease progression during or following platinum-containing chemotherapy Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy [see Clinical Studies (14.2) ]. 1.3 Advanced Renal Cell Carcinoma BAVENCIO in combination with axitinib is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC) [see Clinical Studies (14.3) ] .
label id: 990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start: 1173

current approval status

not_reconciled

duplicate text group

dup-711105299f5f11ac4e31

extraction review status

automated_candidate_pending_source_review

generic names

AVELUMAB

ind-span-8773f1fafb4d9b4bdad4

label id

990c5dd1-5670-4e2f-af5d-6e87b73b12b5

positive predicate support span

end: 1434
end exclusive: true
exact text: is indicated
label id: 990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start: 1422

qualifier mentions

context exact
ated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) who: Have disease progression during or following platinum-contain
kind
biomarker
polarity
not_inferred
span
end
1533
end exclusive
true
exact text
metastatic urothelial carcinoma (UC) who: H
label id
990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start
1490
context exact
ma BAVENCIO is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) who: Have disease progression during or following plat
kind
stage_or_setting
polarity
not_inferred
span
end
1521
end exclusive
true
exact text
locally advanced or metastatic urothelial carcinoma
label id
990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start
1470
context exact
g chemotherapy Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy [see Clinical Studies (14.2) ].
kind
stage_or_setting
polarity
not_inferred
span
end
1701
end exclusive
true
exact text
neoadjuvant or adjuvant treatment with platinu
label id
990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start
1655

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 1758
end exclusive: true
exact text: Previously-treated Urothelial Carcinoma BAVENCIO is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) who: Have disease progression during or following platinum-containing chemotherapy Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy [see Clinical Studies (14.2) ].
label id: 990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start: 1373

source url

https://api.fda.gov/drug/label.json?search=id%3A%22990c5dd1-5670-4e2f-af5d-6e87b73b12b5%22

spl effective date

2026-08-25

spl set id

5cd725a1-2fa4-408a-a651-57a7b84b2118

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 10 · positive indication candidate

application numbers

BLA761049

brand names

BAVENCIO

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1958
end exclusive: true
exact text: ring or following platinum-containing chemotherapy Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy [see Clinical Studies (14.2) ]. 1.3 Advanced Renal Cell Carcinoma BAVENCIO in combination with axitinib is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC) [see Clinical Studies (14.3) ] .
label id: 990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start: 1559

current approval status

not_reconciled

duplicate text group

dup-5321e556d722526b4429

extraction review status

automated_candidate_pending_source_review

generic names

AVELUMAB

ind-span-7b7477546c92f1d5c960

label id

990c5dd1-5670-4e2f-af5d-6e87b73b12b5

positive predicate support span

end: 1843
end exclusive: true
exact text: is indicated
label id: 990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start: 1831

qualifier mentions

context exact
1.3 Advanced Renal Cell Carcinoma BAVENCIO in combination with axitinib is indicated for the first-line tre
kind
stage_or_setting
polarity
not_inferred
span
end
1806
end exclusive
true
exact text
Advanced Renal Cell Carcinoma BAVENCIO in c
label id
990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start
1763
context exact
is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC) [see Clinical Studies (14.3) ] .
kind
stage_or_setting
polarity
not_inferred
span
end
1933
end exclusive
true
exact text
advanced renal cell carcinoma (RCC) [see Cl
label id
990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start
1890
context exact
BAVENCIO in combination with axitinib is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC) [see Clinical Studies (14.3) ] .
kind
prior_therapy_or_line
polarity
not_inferred
span
end
1951
end exclusive
true
exact text
first-line treatment of patients with advanced renal cell carcinoma (RCC) [see Clinical Studies (14
label id
990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start
1852
context exact
1.3 Advanced Renal Cell Carcinoma BAVENCIO in combination with axitinib is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC) [see Clinical Studies (14.3) ] .
kind
regimen
polarity
not_inferred
span
end
1951
end exclusive
true
exact text
in combination with axitinib is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC) [see Clinical Studies (14
label id
990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start
1802

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 1958
end exclusive: true
exact text: 1.3 Advanced Renal Cell Carcinoma BAVENCIO in combination with axitinib is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC) [see Clinical Studies (14.3) ] .
label id: 990c5dd1-5670-4e2f-af5d-6e87b73b12b5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: ee94c4359d9d68823f2c72071b40190fc0b529fd149cee1822f57991d54267de
start: 1759

source url

https://api.fda.gov/drug/label.json?search=id%3A%22990c5dd1-5670-4e2f-af5d-6e87b73b12b5%22

spl effective date

2026-08-25

spl set id

5cd725a1-2fa4-408a-a651-57a7b84b2118

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Preserved source evidence · Not medical advice